Skip Navigation
Leading research to understand, treat, and prevent infectious, immunologic, and allergic diseases
Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

Clinical Parasitology Section

Laboratory of Parasitic Diseases

Major Areas of Research

  • Clinical definition and pathogenesis underlying parasitic diseases
  • New methods of diagnosis of parasitic infections
  • Therapeutic interventions in parasitic infections
  • Hypereosinophilic syndromes (HES): from pathogenesis to novel therapeutic interventions
 

Program Description

The Clinical Parasitology Section is an interdisciplinary group of clinically trained LPD staff members who oversee the clinical research portfolio and provide clinical care, consultations, and training in tropical medicine and parasitology. The overriding goals of this program are

  • To gain insight into the clinical syndromes associated with parasitic infections
  • To understand and help define the pathogenesis underlying clinical disease
  • To identify better ways of treating individual infections and to prevent secondary consequences of treatment
  • To develop better diagnostic tools for the species-specific diagnosis of active parasitic infection

Although the Clinical Parasitology Section has protocols to see patients with any parasitic infection, the overwhelming majority of patients have neurocysticercosis, filarial infections (lymphatic filariasis, onchocerciasis, loiasis, mansonellosis), strongyloidiasis, hookworm infections, ascaraisis, giardiasis, echinococcosis, and leishmaniasis. We occasionally see patients with gnathostomiasis, African trypanosomiasis, Chagas disease, and malaria, among others.

back to top

Selected Publications

Bisoffi Z, Buonfrate D, Sequi M, Mejia R, Cimino RO, Krolewiecki AJ, Albonico M, Gobbo M, Bonafini S, Angheben A, Requena-Mendez A, Muñoz J, Nutman TB. Diagnostic accuracy of five serologic tests for Strongyloides stercoralis infection. PLoS Negl Trop Dis. 2014 Jan 9;8(1):e2640.

Khoury P, Herold J, Alpaugh A, Dinerman E, Holland-Thomas N, Stoddard J, Gurprasad S, Maric I, Simakova O, Schwartz LB, Fong J, Lee CC, Xi L, Wang Z, Raffeld M, Klion AD. Episodic angioedema with eosinophilia (Gleich syndrome) is a multilineage cell cycling disorder. Haematologica. 2015 Mar;100(3):300-7.

Mahanty S, Orrego MA, Mayta H, Marzal M, Cangalaya C, Paredes A, Gonzales-Gustavson E, Arroyo G, Gonzalez AE, Guerra-Giraldez C, García HH, Nash TE; Cysticercosis Working Group in Peru. Post-treatment vascular leakage and inflammatory responses around brain cysts in porcine neurocysticercosis. PLoS Negl Trop Dis. 2015 Mar 16;9(3):e0003577.

Nash TE, Mahanty S, Loeb JA, Theodore WH, Friedman A, Sander JW, Singh G, Cavalheiro E, Del Brutto OH, Takayanagui OM, Fleury A, Verastegui M, Preux PM, Montano S, Pretell EJ, White AC Jr, Gonzales AE, Gilman RH, Garcia HH. Neurocysticercosis: A natural human model of epileptogenesis. Epilepsia. 2015 Feb;56(2):177-83.

O'Connell EM, Nutman TB. Eosinophilia in infectious diseases. Immunol Allergy Clin North Am. 2015 Aug;35(3):493-522.

Clinical Trials

Domestic (NIH Clinical Center, Bethesda, Maryland)

Parasitic Infections of the Gastrointestinal Tract, NCT00001162

Treatment of Patients With Cysticercosis With Praziquantel or Albendazole, NCT00001205

Host Response to Infection and Treatment in Filarial Diseases, NCT00001230

Activation and Function of Eosinophilia Conditions With Blood or Tissue Eosinophilia, NCT00001406

Evaluation, Treatment, and Monitoring of Patients With A Known or Suspected Parasitic Infections, NCT00001645

Brain Tissue Swelling and Seizure Activity in Inactive Cysticercosis, NCT00001912

Diagnosis and Treatment of Leishmanial Infections, NCT00344188

Imatinib Mesylate To Treat Myeloproliferative Hypereosinophilic Syndrome, NCT00044304

A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression, NCT00091871

Compassionate Use of Mepolizumab Treatment in Subjects with Hypereosinophilic Syndrome, NCT00244686

A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Single-Dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa loa Infection, NCT01111305

Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome, NCT02130882

Immune Responses to Mycobacterium Tuberculosis (Mtb) in People With Latent Tuberculosis Infection With or Without Concomitant Helminth Infection, NCT02225158

Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome, NCT02101138

People Presenting With Neurocysticercosis in North America, NCT02233855

Steroid Treatment for Hypereosinophilic Syndrome, NCT01524536

 

International

Host Response to Infection and Treatment in Lymphatic Filarial Disease in India, NCT00342576

Effect of Filarial Infection on Immune Responses in Latent Tuberculosis, NCT01547884

A double-blinded, randomized, placebo-controlled dose escalation study to examine the microfilaricidal kinetics and safety of imatinib for the treatment of Loa loa

Effect of concomitant Mansonella perstans microfilaremia on immune responses following single dose praziquantel in subjects with schistosomiasis: a pilot study

back to top

 
 

Last Updated March 16, 2015

Last Reviewed September 11, 2012